Core Viewpoint - The company announced the cancellation of 574,575 restricted stocks that were granted but not vested under the 2023 restricted stock incentive plan due to certain conditions not being met [5][6][7]. Group 1: Decision Process and Disclosure - The company held board and supervisory meetings to review and approve the relevant proposals regarding the 2023 restricted stock incentive plan [1][2]. - Independent directors provided independent opinions on the incentive plan, confirming the legitimacy of the granted stocks [3][5]. Group 2: Cancellation Details - A total of 91,650 shares were canceled due to three initial grantees leaving the company, which disqualified them from the incentive plan [5]. - Additionally, 482,925 shares were canceled because the company's 2024 revenue did not meet the performance assessment criteria set in the incentive plan [6]. Group 3: Impact on the Company - The cancellation of these restricted stocks is not expected to have a substantial impact on the company's financial status or operational results [6][7]. - The management team remains committed to fulfilling their responsibilities and creating value for shareholders [6]. Group 4: Committee Opinions - The Compensation and Assessment Committee and the Supervisory Committee both agreed that the cancellation of the unvested restricted stocks complies with relevant laws and regulations, and does not harm the interests of shareholders [7]. Group 5: Legal Opinion - The legal opinion concluded that the company has obtained the necessary approvals for the cancellation and that the action aligns with applicable laws and the provisions of the incentive plan [7].

证券代码：688655 证券简称：迅捷兴 公告编号：2025-056 深圳市迅捷兴科技股份有限公司 关于向 2025 年限制性股票激励计划激励对象 授予预留部分限制性股票的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 ? 限制性股票预留授予日：2025 年 8 月 21 日 ? 限制性股票预留授予数量：13.36 万股，约占目前公司已发行股份总数 ? 股权激励方式：第二类限制性股票 《深圳市迅捷兴科技股份有限公司 2025 年限制性股票激励计划（草案）》 （以下简称"《激励计划（草案）》"）规定的限制性股票授予条件已经成就， 根据深圳市迅捷兴科技股份有限公司（以下简称"公司"）2025 年第一次临时 股东大会授权，公司于 2025 年 8 月 21 日召开的第四届董事会薪酬与考核委员 会第一次会议、第四届董事会第二次会议，审议通过了《关于向 2025 年限制性 股票激励计划激励对象授予预留部分限制性股票的议案》，确定公司 2025 年限 制性股票激励计划（以下简称"本次激励计划"）的预留授予日为 202 ...

Core Viewpoint - Anhui Anke Biotechnology (Group) Co., Ltd. has announced the repurchase and cancellation of 276,500 restricted stocks from its third phase incentive plan due to 15 incentive targets no longer meeting the incentive conditions [1][4][11]. Summary by Relevant Sections Announcement of Repurchase - The company held a board meeting on August 20, 2025, where it approved the repurchase of restricted stocks that do not meet incentive conditions, totaling 276,500 shares, which accounts for 0.02% of the company's total share capital [1][4]. - The repurchase includes 174,000 shares from the initial grant and 102,500 shares from the reserved grant [1][4]. Approval Process - The third phase incentive plan underwent necessary approval procedures, including independent opinions from the board and verification by the supervisory board [1][2][3]. - The company disclosed the list of incentive targets and did not receive any objections during the public notice period [2][3]. Repurchase Details - The repurchase price for the initial grant is set at 4.81 yuan per share, while the reserved grant is set at 5.27 yuan per share [4][10]. - The total funds used for the repurchase amount to 1,377,115.00 yuan, sourced from the company's own funds [4][10]. Impact on Company Structure - Following the repurchase, the company's total share capital will decrease by 276,500 shares, with no significant impact on the company's operational performance or management diligence [10][11]. - The total share capital before the repurchase was 1,672,521,258 shares, which will be reduced to 1,672,244,758 shares post-repurchase [10]. Opinions from Committees - The Compensation and Assessment Committee and the Supervisory Board have both expressed their agreement with the repurchase, confirming it aligns with relevant regulations and does not harm the interests of the company or its shareholders [11][11].

Core Points - The second unlock period of the 2023 restricted stock incentive plan has been achieved, allowing 125 incentive recipients to unlock a total of 3,138,000 shares, which accounts for 0.3483% of the company's total share capital of 900,986,228 shares [1][18][4] Summary by Sections Incentive Plan Overview - The incentive plan involves granting 11.83 million restricted shares, representing approximately 1.33% of the company's total share capital at the time of the plan's announcement [2] - The plan's effective period lasts up to 48 months from the completion of the restricted stock grant registration [2] Unlock Conditions - The unlock periods are set at 12 months, 24 months, and 36 months from the grant registration date, with specific percentages of shares unlocking at each interval: 40% after the first year, 30% after the second year, and 30% after the third year [2][9] - If performance targets are not met, the company will repurchase the unfulfilled shares at the grant price plus the bank's current deposit interest rate [4][5] Performance Assessment - The performance assessment for the company spans three fiscal years (2023-2025), with specific revenue targets set for each unlock period: - 6.721 billion yuan for the first unlock period - 13.846 billion yuan for the second unlock period - 21.398 billion yuan for the third unlock period [4][14] - Individual performance assessments will also determine the actual unlock amounts for each recipient [4][14] Approval Process - The board of directors and the supervisory board have approved the incentive plan and the unlock conditions, confirming that all procedures are compliant with relevant regulations [18][5] - The legal opinion confirms that the necessary approvals for the unlock have been obtained and that the conditions for unlocking have been met [18] Specifics of the Unlock - The unlock involves 125 recipients, with a total of 3,138,000 shares being released from restrictions [1][18] - The company will issue a notice regarding the unlock before the shares are listed for trading [1]

Core Viewpoint - Jiangsu Changbao Steel Pipe Co., Ltd. has announced the repurchase and cancellation of 180,000 shares of restricted stock from its 2023 incentive plan due to the departure of two incentive targets, which is 1.58% of the total granted shares [1][7]. Summary by Sections Decision Process and Disclosure - The company held multiple board and supervisory meetings to approve the 2023 restricted stock incentive plan and its related management measures [2][3]. - The names and positions of the incentive targets were publicly disclosed without any objections during the internal announcement period [2]. - The first temporary shareholders' meeting in 2023 approved the incentive plan and authorized the board to handle related matters [3]. Repurchase Price Adjustment - The repurchase price for the restricted stock was adjusted to 3.31 RMB per share after accounting for a cash dividend of 0.22 RMB per share [6][7]. - The total estimated amount for the repurchase is 595,800 RMB, funded entirely by the company's own resources [7]. Reasons for Repurchase and Stock Structure Changes - The repurchase is due to the departure of two incentive targets who no longer meet the criteria set in the incentive plan [7]. - Following the repurchase, the total share capital will decrease from 900,986,228 shares to 900,806,228 shares, with a slight change in the proportion of restricted shares [8]. Impact on Company Operations - The adjustments in repurchase price and cancellation of restricted stock are not expected to materially affect the company's operational performance or management diligence [9]. - The supervisory board and the remuneration and assessment committee have both approved the legality and compliance of the repurchase and price adjustment procedures [9][10].

Group 1 - The fifth meeting of the board of directors of Suzhou Sega Technology Co., Ltd. was held on August 21, 2025, with all five directors present, complying with relevant regulations [1] - The board approved the full and summary reports for the first half of 2025, which were published on the same day [1][2] - The board's resolutions included the repurchase and cancellation of 60,000 restricted stocks due to two incentive targets leaving the company [2][3] Group 2 - The board proposed amendments to the company's articles of association and related systems, which will be submitted for approval at the second extraordinary general meeting of shareholders in 2025 [2][3] - The board approved the renaming and revisions of the shareholders' meeting rules, which will also be submitted for shareholder approval [3][4] - Various internal management systems, including those for independent directors, audit committees, and investment management, were revised and published [4][5][6] Group 3 - The board approved the grant of 870,000 restricted stocks to 37 eligible incentive targets at a price of 4.34 yuan per share, with the grant date set for August 22, 2025 [10] - The second extraordinary general meeting of shareholders is scheduled for September 8, 2025, to review the proposals from the board and supervisory committee [10]

Core Viewpoint - Jiangzhong Pharmaceutical Co., Ltd. is implementing a buyback and cancellation of certain restricted stocks as part of its 2021 stock incentive plan, which aims to enhance employee motivation and ensure sustainable development [1][5][10]. Summary by Sections Legal Framework - The legal opinion is based on the Company Law, Securities Law, and relevant regulations regarding stock incentive management [2][3]. - The law firm confirms that the company has provided all necessary and truthful documentation for the issuance of this legal opinion [3]. Buyback Authorization - The buyback plan has been approved by the company's board and is in compliance with the relevant legal requirements [4][10]. - The company aims to establish a long-term incentive mechanism to motivate core employees and does not harm the interests of the company or its shareholders [5][10]. Buyback Details - The buyback is due to certain employees no longer meeting the incentive conditions, resulting in the cancellation of 42,733 shares, which is 0.0067% of the total share capital [11]. - The adjusted buyback price is set at 2.0998 yuan per share, based on previous cash dividends [12][13]. - The total amount for the buyback is 89,730.75 yuan, sourced from the company's own funds [12][13]. Conclusion - The legal opinion concludes that the company has fulfilled the necessary legal procedures for the buyback and cancellation of shares, and further actions will be taken in accordance with relevant regulations [13].

证券代码：600750 证券简称：江中药业 公告编号：2025-043 江中药业股份有限公司 关于 2021 年限制性股票激励计划回购注销部分 限制性股票及调整回购价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●根据 2021 年第二次临时股东大会授权，本次回购注销部分限制性股票属 授权董事会决策事项，无须提交公司股东大会进行审议； ●本次回购注销的限制性股票数量：合计 42,733 股，涉及人数 9 人； ●本次回购限制性股票的价格：42,733 股限制性股票的回购价格为 2.0998 元/股，回购金额共计 89,730.75 元，均为公司自有资金。 江中药业股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开第十 届董事会第七次会议和第十届监事会第七次会议，审议通过了《关于回购注销 部分激励对象已获授但尚未解除限售的限制性股票及调整回购价格的议案》。鉴 于 1 名激励对象因辞职已不符合激励条件，8 名激励对象年度个人绩效考核不 符合第三个解除限售期全部解锁要求，根据《江 ...

Core Viewpoint - The company has completed the repurchase and cancellation of 1,010,439 restricted stocks from its 2022 incentive plan, affecting 322 individuals, which represents 0.0752% of the total share capital before the repurchase [1][18][21]. Summary by Sections 1. Overview of the 2022 Restricted Stock Incentive Plan - The plan was approved in a series of meetings, including the draft and management methods, with independent directors expressing agreement [1][2]. - The initial grant of restricted stocks was made to 289 individuals at a price of 18.25 yuan per share, totaling 2.5901 million shares, with the listing date on April 11, 2022 [3]. 2. Repurchase and Cancellation of Restricted Stocks - The company has conducted multiple rounds of repurchase and cancellation due to various reasons, including the departure of incentive targets and performance not meeting the required standards [8][11]. - The total number of stocks repurchased includes 12,586 shares from two individuals, 44,051 shares from three individuals, and 2,102,440 shares from 360 individuals, among others [8][11][12]. - The repurchase prices for the stocks varied, with prices of 11.826745 yuan and 11.41 yuan per share, leading to a total expenditure of approximately 12,580,148.87 yuan [1][10][18]. 3. Impact on Share Capital Structure - Following the repurchase, the total share capital decreased from 1,342,902,078 shares to 1,341,891,639 shares, with the proportion of restricted stocks also adjusted accordingly [20]. - The structure of the share capital post-repurchase indicates a slight change in the proportion of restricted shares, which now stands at 0% [20]. 4. Financial Implications - The repurchase and cancellation of restricted stocks are not expected to have a significant impact on the company's financial status or operational performance [21].

Core Points - The company reported a significant increase in operating revenue for the first half of 2025, reaching approximately 171.66 million yuan, which represents a 66.23% increase compared to the same period last year [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 11.29 million yuan, a decline of 139.22% compared to a profit of 4.43 million yuan in the previous year [1] - The net cash flow from operating activities was negative at approximately -18.85 million yuan, marking a 117.63% decrease from a positive cash flow of 3.32 million yuan in the same period last year [1] - Basic and diluted earnings per share were both reported at 0.03 yuan, a significant improvement from -0.09 yuan in the previous year, reflecting a 133.33% increase [1][2] - The weighted average return on net assets was 0.55%, an improvement from -1.35% in the previous year [2] - The total assets of the company showed a slight decrease of 0.13% compared to the previous year [2] - The company has implemented changes in accounting policies, specifically regarding warranty costs, which are now included in operating costs as per new guidelines [2] - The company has approved a stock incentive plan for 2025, granting 3.3 million shares of restricted stock to 69 incentive targets, with the grant date set for June 17, 2025 [4]